

**NCIC CLINICAL TRIALS GROUP
SPRING MEETING 2006**

**PSYCHOSOCIAL ONCOLOGY
RESEARCH WORKING GROUP**

**-OPEN MEETING-
AGENDA**

Friday April 28 2006 - 8:30 a.m. – 1:00 pm

Room: Salon Verriere

Chairs: Anne Leis and Zeev Rosberger

8:30 am	Welcome and introductions	A. Leis/Z. Rosberger
8:40 pm	<ul style="list-style-type: none"> • Minutes of last meeting (october 2005) • Update on the PRWG mandate • Update on PRWG membership 	A. Leis/Z. Rosberger H. Richardson
8:50 am	<ul style="list-style-type: none"> • Results of the RFA and update • Lessons learnt • Mechanisms for connecting with these pilot studies' teams • Remaining budget 	H. Richardson A. Leis
9:30 am	<ul style="list-style-type: none"> • Role of prevention research within NCIC-CTG 	H. Richardson
10:00 am	<p>Update from present members re: liaison with tumour groups and studies (PPT presentations) following by discussion</p> <p>Brain: (Maureen Parkinson)</p> <ul style="list-style-type: none"> • CE5: Add socio-demographics questions for the Canadian module and a distress scale. EORTC-QOL BR module is being collected. <p>Prostate: (John Robinson & Michael Brundage)</p> <ul style="list-style-type: none"> • Psychosocial distress will be used as an outcome and predictor of retention in an RTC of immediate intervention vs. watchful waiting for men with low risk prostate cancer. <p>GY: (Zeev Rosberger)</p> <ul style="list-style-type: none"> • OV 12 (A. Leis), OV 13, OV 14, EN5 <p>Symptom Control (Gillian Fyles with SCRN Palliative Care team)</p> <ul style="list-style-type: none"> • Implementation of an Innovative Delirium Screening and Monitoring Instrument (NuDESC) in community palliative care units. • Fatigue (Anne Leis/Rebecca Wong) <p>GI (Anne Leis)</p> <ul style="list-style-type: none"> • CO17- Phase II trial of oral chemotherapy in an elderly population (2 arms). 	All
11:00am	Development of a sociodemographic collection tool	All

11:30am	News ideas and next steps	All
12:00 pm to 1:15 pm	WORKING LUNCH with QOL committee Data bank of question items or tools and measures re: psychosocial outcomes which are suitable for trials.	